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Summary
Two familial and seven sporadic patients with neurofi-
bromatosis 1—who showed dysmorphism, learning dis-
abilities/mental retardation, and additional signs and
carried deletions of the NF1 gene—were investigated by
use of a two-step FISH approach to characterize the
deletions. With FISH of YAC clones belonging to a 7-
Mb 17q11.2 contig, we estimated the extension of all
of the deletions and identified the genomic regions har-
boring the breakpoints. Mosaicism accounted for the
mild phenotype in two patients. In subsequent FISH ex-
periments, performed with locus-specific probes gener-
ated from the same YACs by means of a novel procedure,
we identified the smallest region of overlapping (SRO),
mapped the deletion breakpoints, and identified the
genes that map to each deletion interval. From centro-
mere to telomere, the ∼0.8-Mb SRO includes sequence-
tagged site 64381, the SUPT6H gene (encoding a tran-
scription factor involved in chromatin structure), and
NF1. Extending telomerically from the SRO, two ad-
ditional genes—BLMH, encoding a hydrolase involved
in bleomycin resistance, and ACCN1, encoding an ami-
loride-sensitive cation channel expressed in the CNS—
were located in the deleted intervals of seven and three
patients, respectively. An apparently common centrom-
eric deletion breakpoint was shared by all of the patients,
whereas a different telomeric breakpoint defined a de-
letion interval of 0.8–3 Mb. There was no apparent cor-
relation between the extent of the deletion and the phe-
notype. This characterization of gross NF1 deletions
provides the premise for addressing correctly any ge-
notype-phenotype correlation in the subset of patients
with NF1 deletions.
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Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dom-
inant condition (MIM 162200) mapped to chromosome
17q11.2. Following positional cloning of the NF1 gene
(Cawthon et al. 1990; Viskochil et al. 1990; Wallace et
al. 1990), the whole cDNA has been assembled and se-
quenced. However, despite advances in the definition of
NF1-gene structure (Li et al. 1995), that the complete
genomic sequence is not yet available is one of the factors
that hamper the identification of NF1 mutations. The
mutation rate of NF1 (3 # 105 to 1# 104) is higher
than that of most human genes (Stevenson and Kerr
1967; Vogel and Motulsky 1997) and accounts for the
substantial fraction (150%) of de novo patients with
NF1. According to the NNFF InternationalNF1Genetic
Analysis Consortium, 246 NF1 mutations had been
characterized through February 1999, including 18 de-
letions of the entire gene (NF1 International Consortium
1999). Although the majority of small NF1 deletions/
point mutations are of paternal origin, large NF1-gene
deletions arise preferentially on the maternal chromo-
somes, which suggests that the molecular mechanism
involved in the generation of the deletion is recombi-
nation (Lazaro et al. 1996). No genotype-phenotype cor-
relation has so far been identified for NF1, with the
exception that deletions of the entire gene have been
associated with a severe phenotype that includes dys-
morphism, mental retardation, and the early onset of a
large number of neurofibromas (Kayes et al. 1994; Wu
et al. 1995, 1997a, 1997b; Lazaro et al. 1996; Leppig
et al. 1996; Riva et al. 1996; Upadhyaya et al. 1998).
A study aimed at establishing whether the phenotypic
traits usually associated with complete gene deletions
might be predictive for the deletion subset confirmed this
trend but pointed out that the presence of a deletion
cannot be predicted solely on the basis of clinical phe-
notype (Tonsgard et al. 1997). Precise characterization
of the extent of deletion is a crucial step toward ad-
dressing genotype-phenotype correlations and investi-
gating whether common deletion breakpoints are found
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in different patients. FISH has proved to be useful for
this purpose and also permits the detection of somatic
mosaicism, which may modulate NF1 phenotypic ex-
pression (Ainsworth et al. 1997). We have recruited a
group of nine patients with NF1, including seven spo-
radic and two familial cases, who were known either,
from previous FISH characterization, to carry large de-
letions (Wu et al. 1995; Riva et al. 1996;Wu et al. 1997a,
1997b) or, from LOH analysis, to carry intragenic de-
letions. We have characterized the different deletions by
FISH, using (1) YAC/PAC clones of a contig, assembled
in our laboratory, that is centered on the NF1 gene and
encompasses 17 Mb and (2) locus-specific probes gen-
erated from YAC clones by means of a recently described
procedure (Riva et al. 1999). Using this combined FISH
approach, we have been able to identify an SRO, to
estimate the extent of the deletions, and to define their
boundaries.
Methods
Patients
Recruitment.—Recruitment of the NF1-deleted pa-
tients was performed by FISH analysis for patients 363
and 992 and by loss-of-heterozygosity (LOH) study for
patients M.M., N.C., and N.R. (N.C.’s father), for all
of whom no published information is available. The clin-
ical phenotype and preliminary FISH characterization
have been reported for patients 323 and 665 (Wu et al.
1995), B.L. (Riva et al. 1996), 870 (Wu et al. 1997a),
and 940 and 629 (Wu et al. 1997b). The clinical phe-
notype and background laboratory characterization of
all of the patients are given in table 1.
YAC and PAC preparation.—The YAC clones 884g6,
810f5, 819d12, 909f1, 947g11, 815b11, 946h1,
747h12, 731h4, and 728f1 from the CEPH library (Chu-
makov et al. 1995) and PAC 1002g3 from the RPCI-5
library were obtained from the Department of Biological
and Technological Research resource center at San Raf-
faele Hospital in Milan. The cultures from single colo-
nies were grown in selective AHC medium and were
resuspended in 100-ml LMP (Biorad) agarose plugs con-
taining 7 # 107 cells.
The Alu 153, 154, 451, and 450 primers (Breen et al.
1992) were used for the specific amplification of YAC
DNA from a total-yeast-DNA preparation. The PCR
reactions contained 2 ml of the molten yeast plug as a
template; 1 mM each of Alu 153, 154, 451, and 450
primers; 1 U of Taq polymerase (Bioline); 1.5 mM
MgCl2; and 200 mM each of dNTP, in a total reaction
volume of 50 ml. Thirty-five PCR cycles were performed
at 94C for 1 min, 55C for 1 min, and 72C for 2 min.
Preparation of Locus-Specific Probes
Previously described in detail by Riva et al. (1999),
the method is based on two consecutive reactions using
YAC clones containing the loci of interest. In brief,
using a specific primer, single-strand DNA polymeri-
zation is performed (35 cycles at 94C for 30 s, at
optimal annealing temperature for 1 min, and at 72C
for 2 min), yielding DNA fragments of 0.6–5 kb. The
use of two locus-specific primers—extending the po-
lymerization, in independent reactions, in two opposite
directions—allows coverage of 10 kb around the se-
lected locus. An aliquot (1 ml) of locus-specific single-
strand product is then used as a template in four in-
dependent PCRs performed with four different Alu
primers combined with the locus-specific primer (35
cycles at 94C for 1 min, 55C for 1 min, and 72C
for 2 min). The Alu PCR products were then collected
and precipitated. The probes specific for the following
17q11.2 genes/sequence-tagged sites (STSs), listed in
centromere-to-telomere order, were generated from the
YACs to which they are anchored (see table 3): NOS2A,
D17S1317, 64381, SUPT6H, NF1 [IVS27, IVS38, 3′
UTR], D17S145, BMLH, D17S1863, ACCN1,
D17S1558, D17S798, 64384, 64382, and MCP-3. The
primer pairs for all of the loci are given in Genome
Database (1999). The primers specific for the novel
STSs 64381, 64384, and 64382 are, respectively, 5′-
gcccggccacggctaactt-3′ and 5′-gattacggaattaatgaggcc-3′,
5 ′-atcttgttgggtatgtaagc-3 ′ and 5 ′-ccttccgttaaatgc-
tctg-3′, and 5′-gatggttagcagctttgctc3′ and 5′-ggttgccca-
tattgagtctg-3′.
FISH
The precipitated DNAs were resuspended in 100 ml
of Tris 10 mM EDTA 1 mM, and 1 mg of each probe
was labeled with digoxigenin-dUTP (Boehringer Mann-
heim) by use of a nick-translation kit (BoehringerMann-
heim). One hundred nanograms of labeled probe were
precipitated with 10 mg of salmon sperm and 5 mg of
Cot-1 DNA (Boehringer Mannheim) and were resus-
pended in 15 ml of hybridization buffer (50% formam-
ide, 2 # SSC, 10% dextran sulfate, 0.1% Tween 20).
The probes were denatured at 72C for 7 min and then
preincubated at 37C for 30 min. Chromosomal spreads
from peripheral blood lymphocytes were denatured in
70% formamide, 2 # SSC for 2 min and then were
immediately dehydrated in the ethanol series (70%,
90%, and 100%).
The FISH experiments were done according to stan-
dard procedure (Lichter and Cremer 1992). Only the
first phase of the detection protocol was performed with
the fluorescein-labeled detection of digoxigenin-labeled
probes (Oncor). The chromosomes were counterstained
with propidium iodide (0.6 mg/ml) in antifade (Oncor)
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Figure 1 Schematic physical map of the region centered on the NF1 gene and extending from D17S841 to D17S1842. Genes (boldface
italics), STRs (boldface), and STSs (normal font) are ordered from centromere to telomere. Ten YACs (thicker lines) and one PAC (thinner line)
are shown, selected from a 17q11.2 contig comprising 23 YACs and 8 PACs and covering ∼7 Mb in a genetic interval of 9 cM. Sixteen locus-
specific probes (⊥) are also shown, under the corresponding loci between the map and the YACs from which they were generated.
and then were visualized by means of a Leitz DM-RB
microscope equipped for DAPI and FITC/TRITC epiflu-
orescence optics. The images were captured with a CCD
camera (3CCD camera C5810; Hamamatsu) and visu-
alized by Highfish software (Casti Imaging).
Results
All of the 11 patients included in this study had NF1
diagnosed by conventional clinical criteria. Six had a
preliminary FISH characterization that indicated a large
deletion, and two (M.M. and N.R’s daughter) were
found to be hemizygous by means of LOH segregation
analysis at NF1 IVS27Ac28.4 and IVS38TG53.0 micro-
satellites. All of the patients had a severe NF1 phenotype
with a number of other clinical features (table 1).Mental
retardation, as assessed by IQ testing, ranges from severe
(in patients 665, 323, and B.L.) to mild (629) or bor-
derline (M.M.). It is worth noting that, of the five pa-
tients not showing mental retardation, 870 and N.R.
were found by previous (Wu et al. 1997a) or present
FISH characterization to be mosaics. As shown in table
1, craniofacial dysmorphisms were present in nine pa-
tients: facial photographs have been published for pa-
tients 323 and 665 (Wu et al. 1995), B.L. (Riva et al.
1996), 870 (Wu et al. 1997a), and 629 and 940 (Wu et
al. 1997b). In joint evaluation of reported and novel
cases, coarse facial features were displayed by 363, 992,
and B.L.; down-slanting and bulbous nasal tips were
shared by patients 870, 992, 629, 940, 323, M.M., and
B.L.. Patient 992 also showed epicanthic folds and low-
set posteriorly rotated ears, features also present in pa-
tient 323, who had prominent forehead, flame nevus,
and broad neck (Wu et al. 1995). Patient M.M. had
mild malar hypoplasia and mild pterygium, as did B.L.,
who also displayed prominent supraorbita (Riva et al.
1996). Common additional signs were large hands and
feet, whereas skeletal abnormalities were present in three
patients (table 1). The most severe phenotype was de-
tected in B.L., whose characterization has been reported
by Riva et al. (1996). Patients 940 and N.R. transmitted
NF1 to their children, whose clinical signs are also re-
ported in table 1. All the de novo patients, as well as
the parents of the two familial cases, underwent FISH
analysis on lymphocyte metaphases, by a stepwise pro-
cedure. First, mega-YACs and PACs were used to iden-
tify the clones included in the deletion interval (giving
a negative FISH signal) or spanning the deletion break-
points (giving either a decreased or a positive FISH sig-
nal). Then, locus-specific probes were generated from
the YACs by means of a previously reported procedure
(Riva et al. 1999), allowing the extent of the deletion
and its breakpoints to be precisely defined by means of
the presence of negative or positive FISH signals.
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Table 2
FISH Analysis by YACs/PAC
PATIENT
SIGNAL FOR YAC/PAC (OF SIZE)a
y884g6
(.4 Mb)
y810 f5
(1.7Mb)
y909 f1
(.8Mb)
p1002g3
(60 kb)
y947 g11
(1.7 Mb)
y815 b11
(1.5 Mb)
y728f1
(1.7 Mb)
y747h12
(1.3 Mb)
870     /   
363     /   
992     /   
665     /   
940  /   /   
323  /      
N.R.        
M.M.        
B.L.       / 
a  = Positive finding on both chromosomes 17;  = negative finding on one chromosome 17; / =
signal decreased as compared with that on the homologue.
Figure 1 shows a schematic physical map of the region
centered on the NF1 gene and extending from D17S841
(the most centromeric marker) to D17S1842 (the most
telomeric marker). On this map, the known genes and
STSs are ordered from centromere to telomere, accord-
ing to their anchorage to the YACs and PACs, which
are reciprocally aligned below them. The selected YACs
are part of a 17q11.2 YAC/PAC contig consisting of 23
YACs and eight PACs and covering 17 Mb in a genetic
interval of 9 cM (L. Corrado, P. Riva, M. Venturin, A.
Bentivegna, C. Gervasini, and L. Larizza, unpublished
data). For each clone, the size and assessed deletions are
indicated to approximate the extent of the target region.
Sixteen locus-specific probes targeting six genes
(NOS2A, SUPT6H, NF1, BLMH, ACCN1, MCP-3)
and eight D-loci are indicated between the correspond-
ing loci and the YACs from which they were generated.
Table 2 shows the results obtained, on the patients
with NF1 deletions, by means of FISH of the selected
YACs and PAC, which are entered in the table, from left
to right, in centromere-to-telomere order. As can be seen,
YAC 909f1 and PAC 1002g3 did not give a signal on
one chromosome 17 in all of the patients, indicating the
deletion of the target regions. YAC 947g11 had a de-
creased signal on one chromosome 17 in most patients
(6/9) and did not give any signal in patients N.R., M.M.,
and B.L. A decreased signal on one 17 homologue was
also observed for YAC 810f5 in two patients (940 and
323). A lack of signal and a decreased signal were ob-
served for YAC 815b11 and YAC 728f1, respectively,
in patient B.L., who thus bears the largest deletion.
To refine the deletion breakpoints and better estimate
the size of the deletions, a further set of FISH experi-
ments was performed, with use of the locus-specific
probes diagrammed in figure 1. From centromere to tel-
omere along the contig YACs used in the initial FISH
characterization, FISH probes specific for NOS2A and
D17S1317 were generated from y819d12, to which they
are anchored. SUPT6H- and 64381-specific probes were
produced from y909f1. The probes targeted on anon-
ymous DNA fragments such as D17S145 and
D17S1863, intragenic NF1 markers, and the BLMH
gene were developed from y947g11. The two STSs
D17S1558 and D17S798 and the ACCN1 gene were
generated from y815b11, STSs 64384 and 64382 were
obtained from y946h1, and an MCP-3 specific probe
was generated from y728f1. As outlined in table 3, these
second-round FISH experiments allowed us to map the
distal deletion breakpoints for all of the patients except
patient 940. From centromere to telomere along the in-
terval that includes the 3′ breakpoints, D17S145 is the
telomeric boundary of the deletion in patient 870. The
distal deletion limit could be identified at the BLMH
gene in patient 363, at D17S1863 in patients 992 and
665, at ACCN1 in patient 323, at D17S1558 in N.R.,
and at D17S798 in M.M. Patient B.L. was found to have
deletions at STSs 64384 and 64382. MCP-3, anchored
to y728f1 at the telomeric portion of the contig, is pre-
sent in all patients, including B.L., whose distal break-
point is fixed to this gene. With regard to the proximal
deletion breakpoint, D17S1317 appears to be the cen-
tromeric boundary in most patients. As indicated in table
3, patients 363, 992, 940, and 323 could not be fully
investigated, because of shortage of material.
In figure 2, representative examples of the higher res-
olution of locus-specific probes are shown, in compar-
ison with whole-YAC probes, to define the telomeric
boundaries of the deletions of eight patients. For each
patient, the upper panel shows the results of YAC FISH,
and the lower panel shows the results of FISH using the
most telomeric locus-specific probe included in the de-
letion. As can be seen, FISH of y947g11 gave a decreased
hybridization signal in the patients whose deletions
could be differentiated after FISH with NF1 3′ UTR–,
S145-, BLMH-, and S1863-specific probes (table 3 and
fig. 2a–e and a′–e′). A shift from YAC 815b11 to
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Table 3
FISH Analysis by Locus-Specific Probes
PATIENT
FINDING AT LOCUS
y819d12
(1.4 Mb)
y909f1
(.8 Mb)
y947g11
(1.6 Mb)
y815b11
(1.5 Mb)
y946h1
(1.2 Mb)
y728f1
(1.3 Mb)
NOS2Aa S1317b 64381b SUPT6Hc int27 int38 3′UTR S145 BLMHd S1863 ACCN1e,b 1558 S798 64384 64382 MCP-3f
870                
363  ND              
992  ND              
665                
940  ND ND        ND     
323  ND              
N.R.                
M.M.                
B.L.                
a NOS2A = nitric oxide synthase 2a.
b ND = no data.
c SUPT6H = suppressor of Ty 6, homologue of S. cerevisiae.
d BMLH = bleomycin hydrolase.
e ACCN1 = cation-channel amiloride-sensitive neuronal 1.
f MCP-3 = monocyte chemotactic protein 3.
ACCN1- and S1558-specific probes made it possible to
differentiate the apparently similar deletions in patients
N.R. and M.M. (table 3 and fig. 2f–g and f′–g′). Probe
64382 targeted the last telomeric sequence deleted in
B.L., allowing us to resolve the 1.7-Mb y728f1 that gave
a decreased signal in the same patient (table 3 and fig.
2h and h′).
Figure 3 compares the deletions carried by the nine
patients, by aligning each one along the genomic region
extending from NOS2A to MCP-3. As can be seen, an
SRO including the SUPT6H gene 5′ to NF1 could be
identified. On the basis of the size of the covering YAC
909f1, the length of the SRO was calculated as being
∼0.8 Mb. All of the patients who could be characterized
by locus-specific probes generated from the most cen-
tromeric y819d12 were found to share D17S1317 as the
proximal boundary, whereas the telomeric boundaries
of the deletions were very different, from that of patient
870, whose deletion overlaps the SRO (0.8 Mb), to that
of patient B.L., whose deletion can be estimated as ∼3
Mb. The deletion in patient 665 could be sized as being
2 Mb, that of patients N.R. and M.M. as being 2.3 Mb.
Because of the low-resolution mapping of the centrom-
eric breakpoint, the extent of the deletion was estimated
as 0.8–1.2 Mb in patient 363 and as 1–1.5 Mb in pa-
tients 992 and 323. The size of the deletion in patient
940 was very approximately estimated as 1.8–2.8 Mb,
because of the poor definition of both breakpoints.
Discussion
We have investigated 11 patients with NF1 who had
a complex phenotype and gross deletions and who rep-
resent the largest subgroup of such unusual patients so
far investigated by FISH analysis. Our aims were to iden-
tify the SRO and extent of the deletion and to assess
possible common deletion breakpoints. We used a step-
wise FISH procedure consisting of YAC FISH followed
by the high-resolution FISH technique using locus-spe-
cific probes (Riva et al. 1999). Associations between de-
letions spanning the NF1 gene and the presentation of
complex NF1 have been described and commented on
in several studies (Kayes et al. 1994; Wu et al.1995,
1997a, 1997b; Leppig et al. 1996; Riva et al. 1996;
Upadhyaya et al. 1996, 1998). One study reviewing 16
patients with NF1 who carried large deletions (12 from
the literature and 4 of novel description) has raised the
question as to whether NF1-gene deletions lead to a
characteristic phenotype (Tonsgard et al. 1997). The au-
thors of that report concluded that, although large NF1
deletions are relatively frequent in patients with facial
dysmorphism, mental retardation/learning disabilities,
and an early onset of multiple neurofibromas, the pres-
ence of the deletion cannot be predicted solely on the
basis of the clinical phenotype.
As shown in table 1, most of our patients (9/11) pre-
sented dysmorphism, although no single dysmorphic
trait was shared by all of them. Nine of the patients
developed neurofibromas, but the onset did not appear
to be any earlier than that in classical NF1. According
to IQ tests, 4 (36%) of our 11 patients were mentally
retarded, a finding consistent with the higher incidence
of mental retardation in the subgroup of NF1-deletion
patients (Tonsgard et al. 1997) than in patients with
classic NF1 (8%–10%) (Ferner 1994). Cardiovascular
anomalies, observed in 2% of patients with NF1 (Fried-
man and Birch 1997) and in 3 of our 11 patients, may
also have a higher incidence in NF1-deletion patients.
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Figure 2 Top, FISH performed with YACs mapped at the telomeric deletion boundary of patients 870, 363, 992, 665, 323, N.R., M.M.,
and B.L. (a–h, respectively). Bottom, FISH with the most telomeric locus-specific probes included in patients’ deletions (a′–h′, respectively). On
metaphases from patients (a–e), FISH with YAC 947g11 gives a decreased signal on one chromosome 17 (arrowhead) in respect to the homologue
(arrow): each patient’s deletion can be differentiated by locus-specific–probe FISH, the most telomeric deleted probe being NF1-3′ UTR for
patient 870 (a′), S145 for patient 363 (b′), BLMH for patients 992 and 665 (c′ and d′, respectively) and S183 for patient 323. FISH with YAC
815b11 gives a signal of similar intensity on both chromosomes 17 of patients N.R. and M.M. (f and g, respectively), whose deletions can be
differentiated by probes ACCN1 and S1558 respectively (f′ and g′, respectively). Patient B.L. (h) shows a decreased signal on one chromosome
17 with YAC 728f1 (arrowhead) but is deleted up to the 64382 locus-specific probe (h′).
In agreement with previous findings (Tonsgard et al.
1997), our patients generally have a severe phenotype,
but this did not lead to an early clinical diagnosis of
NF1. Our study also confirms the conclusion of Tons-
gard et al. that the phenotype may not always predict
an extensive gene deletion, as exemplified by our patient
N.C. Interestingly, the father of this patient (N.R.), who
was included in the study following the detection of
LOH at intragenic NF1 markers, proved, on FISH char-
acterization, to be a mosaic, and the same was true for
the mother of the familial case reported in the review
cited above (Tonsgard et al. 1997). Previous studies have
indicated that familial NF1 may contribute to the sub-
group of NF1-deletion patients (Tonsgard et al. 1997;
Wu et al. 1997b), and this is confirmed by our study.
Therefore, patients with both sporadic and familial NF1
who have a severe phenotype should be taken into ac-
count in the search for gross deletions. Furthermore, the
relatively mild phenotype of patients with mosaic NF1,
which is only detectable by FISH methods, may con-
tribute to the underdetection of NF1 deletions.
The characterization of the few NF1-deletion patients
reported in the literature has mainly been based on FISH
analysis with YAC and cosmid clones mapped to the
NF1 gene and its flanking regions. However, because of
the lack of a refined physical map of 17q11.2, this char-
acterization could not be made at high resolution. For
the current FISH analysis, we used ordered clones be-
longing to a 17-Mb YAC/PAC contig that we have re-
cently constructed (Corrado et al. 1999; L. Corrado, P.
Riva, M. Venturin, A. Bentivegna, C. Gervasini, and L.
Larizza, unpublished data). This contig is centered on
the NF1 gene and is distally linked to the chemokine
contig that has also been mapped at 17q11.2 (Naruse
et al. 1996). Using this resource made it possible to cover
nine different deletions in their entirety (table 2). Three
deletion subsets were identified, differentiated mainly at
the telomeric boundary. A further refinement was then
achieved with a new tool, consisting of the “ad hoc”
generation of locus-specific probes from YAC clones en-
compassing the deletion boundaries, that resolved ap-
parently similar deletions and showed that they were
differentiated at the telomeric boundary (fig. 2 and table
3). The SRO could also be precisely identified (fig. 3),
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Figure 3 Deletions carried by the nine patients, compared in terms of their alignment along the 17q11.2 region extending from NOS2A
to MCP-3. The locus-specific probes are ordered from centromere to telomere. The SRO that includes the SUPT6H gene 5′ toNF1 is represented
by a double line and the overall deleted region is represented by a thicker line. All of the patients who could be characterized by locus-specific
probes generated from the most centromeric y819d12 were found to share D17S1317 as a proximal boundary, but all of the deletions are
differentiated at the telomeric boundary. The dashed lines point to regions that YAC FISH showed as spanning the deletion breakpoints but
that may not be included in the deletion interval.
and its gene content could be established on the basis
of the gene mapping of the YAC/PAC contig. The
SUPT6H gene encoding a transcription factor involved
in chromatin structure (Chiang et al. 1996) is the only
extra-NF1 gene lying within the SRO (fig. 3). It is still
unknown whether SUPT6H is a dosage-sensitive gene,
haploinsufficiency of which contributes to the complex
NF1 phenotype.
Centromerically, from the SRO, the first mapped gene
is NOS2A, which was found, in all nine patients, not
to be deleted (fig. 3). Two additional genes, BLMH and
ACCN1, were found to be located in the deleted interval
of seven and three patients, respectively (fig. 3). BLMH
encodes a hydrolase involved in bleomycin resistance
(Lazo and Humphreys 1983), which has been associated
with an increased risk of Alzheimer disease (Montoya
et al. 1998), whereas ACCN1 encodes an amiloride-
sensitive cation channel expressed in the CNS (Garcia-
Anoveros et al. 1997). A common centromeric break-
point appears to characterize all of the patients whose
deletions do not include theNOS2A gene and the nearby
marker D17S1317 (table 3 and fig. 3). More-precise
mapping of the centromeric deletion breakpoints could
not be pursued in four cases.
The telomeric breakpoints were all different, except
in patients 992 and 665. The deletion boundary in pa-
tient 940 was fixed to D17S1558, but the 5′ ACCN1
was not tested, because of inadequate material. The larg-
est deletion, with a breakpoint between 64382 and
MCP-3, was found in patient B.L.; the mapping of his
telomeric breakpoint coincides with the 17q breakpoint
underlying the constitutional translocation t(1;17) found
in a neuroblastoma patient (Van Roy et al. 1997). More
generally, the 17q12-21 region clusters the 17q break-
points of t(1;17), a cytogenetic marker associated with
the development of neuroblastoma and found in a num-
ber of neuroblastoma tumors and cell lines (Van Roy et
al. 1997). The involvement of this chromosomal region
in constitutional and cancer breakpoints suggests the
presence of DNA-sequence motifs that might predispose
to rearrangement.
The finding of a common centromeric breakpoint in
all of our patients may be caused by the structural fea-
tures of the involved regions. Over the past few years,
many microdeletion syndromes have been defined at the
molecular level, and, in some of these syndromes, the
commonly deleted region has been found to be flanked
by low-copy-repeat sequences (Lupsky 1998). The shar-
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ing of a common centromeric breakpoint by a number
of patients with NF1 deletions and the coincidence of
the telomeric breakpoint in a patient with a neuroblas-
toma-specific rearrangement suggest that the NF1-mi-
crodeletion syndrome may be viewed as a genomic dis-
order (Lupsky 1998).
In conclusion, our study demonstrates that the refined
FISH characterization of gross NF1 deletions is feasible
with suitable resources and technologies. Precise defi-
nition of gene/STS content and of the extent and bound-
aries of deletions is a prerequisite for study of the com-
plex problem of genotype-phenotype correlations. This
is beyond the scope of the present study, which should
be seen as a pilot study concentrating on a new method,
the extensive application of which may make it possible
to investigate genotype-phenotype correlations correctly.
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